Results 201 to 210 of about 639,073 (304)

Uncommon Cause of Pulmonary Hypertension: Imaging Diagnosis of Cardiac Myxoma Embolism. [PDF]

Diagnostics (Basel)
Braillon A, Patural P, Laville D, Perros F, Turquier S, Cottin V, L'Huillier R, Si-Mohamed S.   +7 more
europepmc   +1 more source

A promise to save 100,000 trauma patients.

, 2013
Horton, Richard, Krug, Etienne, Mersch, Jeannot, Piot, Peter, Roberts, Ian, Shakur, Haleema   +5 more
core   +1 more source

Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population‐Based Cohort Study Using Antibiotic Dispensing Data

Clinical Pharmacology &Therapeutics, EarlyView.
This study compared the number and cumulative dose of antibiotic dispensings among new users of sodium–glucose cotransporter‐2 (SGLT2) inhibitors and dipeptidyl peptidase‐4 (DPP4) inhibitors following hospital discharge in individuals with type 2 diabetes.
Maria J. Alfonso Arvez, George S. Q. Tan, Sam Wade, Zanfina Ademi, Jenni Ilomäki, J. Simon Bell   +5 more
wiley   +1 more source

Late Onset Pulmonary Arterial Hypertension Associated With Features of Pulmonary Veno-Occlusive Disease and Rare Heterozygous Variants of <i>KDR</i> and <i>EIF2AK4</i>. [PDF]

Pulm Circ
Foris V, Brcic L, Dorfmüller P, Eichstaedt CA, Grünig E, Douschan P, John T, Zeder K, Fuchsjäger M, Kneidinger N, Kovacs G, Olschewski H.   +11 more
europepmc   +1 more source

PULMONARY HYPERTENSION [PDF]

Heart, 1940
openaire   +2 more sources

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT‐ACS Emulation Using National Health Insurance Claims Data

Clinical Pharmacology &Therapeutics, EarlyView.
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang, Yee‐Jen Wu, Fang‐Ju Lin, Chien‐Chih Wu, Hsin‐Yi Huang, Chi‐Chuan Wang, Xiaojuan Li   +6 more
wiley   +1 more source

Identification of potential core genes in idiopathic pulmonary arterial hypertension: An observational study highlighting the role of VEGFA. [PDF]

Medicine (Baltimore)
Zhou Y, Xu L, Ou A, Gan S, Deng W.
europepmc   +1 more source

Expediting Drug Development in Japan: A PMDA Perspective

Clinical Pharmacology &Therapeutics, EarlyView.
Review time for a new drug in Japan has shortened dramatically since the establishment of the Pharmaceuticals and Medical Devices Agency (PMDA). Nonetheless, Japan faces a new challenge so‐called “Drug Loss”, which means that new drugs approved overseas have not yet been developed in Japan or that development is delayed. In this manuscript, we describe
Yoichi Kohno, Akihiro Ishiguro, Takashi Yasukawa, Naoyuki Yasuda, Daisuke Tanaka, Yasuhiro Araki, Yukio Takahashi, Yoshiaki Uyama, Yasuhiro Fujiwara   +8 more
wiley   +1 more source

Correction: Pediatric pulmonary arterial hypertension: global epidemiology and disease burden during the period 1990 to 2021. [PDF]

Front Cardiovasc Med
Chen Y, Zhang R, Zheng Y, Li C, Wang X, Wen Z, Li F.   +6 more
europepmc   +1 more source

Clinical Trials With Pragmatic Elements: A Review of Use Cases and Real‐World Data Utilization

Clinical Pharmacology &Therapeutics, EarlyView.
Clinical trials with pragmatic elements can capture diverse patient populations, enable efficient follow‐up, and reflect routine clinical practices; yet there is limited understanding of their design features, characteristics, and use of real‐world data (RWD). Based on a targeted search of PubMed/EMBASE (Jan‐2016 to Jul‐2024), a review was conducted to
Le Su, Lei Chen, Seema Betigeri, Nancy Dreyer, Helga Gardarsdottir, Rachele Hendricks‐Sturrup, Mehmet Burcu   +6 more
wiley   +1 more source